Login to Your Account

Allecra lands €9M to advance phase III candidate to fight hospital-acquired infections

By Nuala Moran
Staff Writer

Monday, December 4, 2017

LONDON – Allecra Therapeutics GmbH closed a €9 million (US$10.7 million) first tranche of a series C round, enabling it to fund phase III development of AAI-101 in the treatment of serious hospital-acquired gram-negative infections.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription